CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3‐Mediated Neuroinflammation in Neurodegenerative Disease: A Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics.

This Phase 1 study demonstrated a favourable tolerability profile for CVN293 in healthy adults and supports the continued development of this novel KCNK13 inhibitor for neurodegenerative diseases driven by neuroinflammation.